261 related articles for article (PubMed ID: 37137826)
1. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
2. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
[No Abstract] [Full Text] [Related]
3. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis.
Zheng RD; Chen JN; Zhuang QY; Lu YH; Chen J; Chen BF
Int J Med Sci; 2013; 10(5):641-6. PubMed ID: 23569427
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of advanced fibrosis in metabolic dysfunction-associated fatty liver disease patients with chronic hepatitis B].
Wu X; Li P; Mi YQ
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):53-58. PubMed ID: 38186118
[No Abstract] [Full Text] [Related]
5. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study.
Yi S; Ren G; Zhu Y; Cong Q
Virol J; 2024 Jan; 21(1):22. PubMed ID: 38243304
[TBL] [Abstract][Full Text] [Related]
6. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
7. [Exploring the effects of entecavir treatment on the degree of liver fibrosis in patients with non-alcoholic fatty liver combined with chronic hepatitis B in Tibet region].
Wen QP; Qian H; Ba S; Lu MJ; Silang LDJ; Shi L
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):304-308. PubMed ID: 35462487
[No Abstract] [Full Text] [Related]
8. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B.
Jiang C; Liu J; Li R; Chen K; Peng W; Fu L; Peng S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):698-706. PubMed ID: 37539572
[TBL] [Abstract][Full Text] [Related]
9. Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study.
Leow YW; Chan WK; Goh GB; Wong VW; Fan JG; Kim YS; Kim SU; Nakajima A; Seto WK; Lee IC; Huang YH; Kim YJ; Young JJ; Chow WC
J Viral Hepat; 2023 Apr; 30(4):319-326. PubMed ID: 36606597
[TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
11. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
12. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis.
Zheng RD; Xu CR; Jiang L; Dou AX; Zhou K; Lu LG
Int J Med Sci; 2010 Aug; 7(5):272-7. PubMed ID: 20714438
[TBL] [Abstract][Full Text] [Related]
13. MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients.
Chen X; Zhou J; Wu L; Zhu X; Deng H
Diabetes Metab Syndr Obes; 2022; 15():673-683. PubMed ID: 35256849
[TBL] [Abstract][Full Text] [Related]
14. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors.
Minakari M; Molaei M; Shalmani HM; Mohammad Alizadeh AH; Jazi AH; Naderi N; Shavakhi A; Mashayekhi R; Zali MR
Eur J Gastroenterol Hepatol; 2009 May; 21(5):512-6. PubMed ID: 19190500
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
[TBL] [Abstract][Full Text] [Related]
16. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
17. [Prevalence and risk factors of hepatic steatosis in patients with chronic hepatitis B].
Shi JP; Fan JG; Wu R; Gao XQ; Zhang L; Wang H
Zhonghua Gan Zang Bing Za Zhi; 2008 Jul; 16(7):519-23. PubMed ID: 18647531
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of clinical and pathological features of chronic hepatitis B with hepatic steatosis].
Mi YQ; Liu YG; Xu L; Fan JG; Zhang H; Ping L; Shi RF
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):817-20. PubMed ID: 19958639
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection.
Sefa Sayar M; Bulut D; Acar A
Arab J Gastroenterol; 2023 Feb; 24(1):11-15. PubMed ID: 35688683
[TBL] [Abstract][Full Text] [Related]
20. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
